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Summary 
Mice bearing a tumor necrosis factor (TNF) ot transgene controlled by an insulin promoter devel- 
oped an increasingly severe lymphocytic insulitis, apparently resulting from the induction of en- 
dothelial changes with features similar to those observed in other places of intense lymphocytic 
traffic. This was accompanied by dissociation of the endocrine tissue (without marked decrease 
in its total mass), islet fibrosis, and the development of intraislet ductules containing, by places, 
cells in their walls, suggesting a regenerative capacity. Islet disorganization and fibrosis did 
not result from lymphocytic infiltration, since they were also observed in SCID mice bearing 
the transgene. Diabetes  never developed, even though a number of potentially inducing condi- 
tions were used, including the prolonged perfusion of interferon 3' and the permanent expression 
of a nontolerogenic viral protein on/3 cells (obtained by using mice bearing two transgenes). 
It is concluded that (a) a slow process of TNF release in pancreatic islets induces insulitis,  and 
may be instrumental in the insulitis resulting from local cell-mediated immune reactions,  but 
(b) that insulitis per se is not diabetogenic, lymphocyte stimulation by cells other than B cells 
being necessary to trigger extensive B cell damage. This provides an explanation for the dis- 
crepancy between the occurrence of insulitis and that of clinical disease in autoimmune diabetes. 
I 
nsulin-dependent diabetes is thought to be of autoimmune 
origin. In animal models of the human disease, the nono- 
bese diabetic (NOD) 2 mouse (for review see reference 1) and 
the Bio Breeding (BB) rat (2), it begins with a lymphocytic 
insulitis, which can progress towards eventual destruction of 
the insulin-secreting/3 cells. Although the antigenic target(s) 
of the autoimmune reaction taking place in the pancreatic 
islets may be different in human diabetes and animal models, 
destruction of/~  cells probably proceeds through similar 
pathogenetic mechanisms, based on T cell-mediated tissue 
damage. 
1 The contributions of Y. Higuchi and P. Herrera should be considered 
equal. 
2Abbreviations  used in  this paper:  BB,  Bio  Breeding;  LCMV  gp,  lym- 
phochoriomeningitis  virus glycoprotein; NOD, nonobese diabetic; RIP, 
rat insulin promoter. 
Among these pathogenetic mechanisms, direct cytotox- 
icity of T lymphocytes to antigen-bearing ~ cells and release 
of cytokines harmful to/3 cells have been incriminated. Cells 
containing mRNA for perforin, a protein involved in cyto- 
toxicity, and for TNF-c~, a broad mediator of inflammatory 
reaction, have been detected in the insulitis of NOD mice 
by in situ hybridization (3). Based on in vitro alterations  of 
islet cells in the presence of TNF or IL-1, another broad medi- 
ator of inflammation with many effects resembling those of 
TNF, and the potentialization of these effects by IFN-3', a 
product of stimulated lymphocytes, it has been proposed that 
local release of these various cytokines plays a role in the ap- 
pearance of diabetes (4-8). Mice bearing an IFN-'y transgene 
placed under the control of the insulin promoter, and thus 
releasing INF-y in the pancreatic islets through B cells, de- 
velop diabetes (9). Since TNF is a possible mediator of au- 
toimmune ~ cell destruction, we decided to explore the effects 
of/3 cell expression of a TNF transgene.  A severe insulitis 
developed, but, in spite of its persistence,/3 cell damage ex- 
tensive enough to result in diabetes was not observed,  even 
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T lymphocytes within the insulitis to develop a diabetogenic 
immune reaction against/~ cells were made by perfusing other 
cytokines (e.g., IFN-y), by mildly damaging ~ ceils, or/and 
by expressing a viral antigen on B cells (using mice bearing 
an additional transgene) (10). Failure to elicit diabetes in all 
these conditions leads to the conclusion that two successive, 
pathogenically distinct  phases may be required  for the ap- 
pearance of autoimmune diabetes, and that insulitis, the first 
phase,  may be necessary but not sufficient to create diabetes. 
This probably explains why a large proportion of NOD mice, 
which all develop insulitis of comparable severity,  does not 
progress toward diabetes. 
Materials  and Methods 
Mice.  A NarI-SalI fragment containing  all the coding and 3' 
untranslated  regions of the TNF-c~ gene was obtained from a X 
EMBL 3 genomic  clone  containing  most  of the mouse  strain 
C57B1/6 TNF locus (11) and inserted behind a 660-bp fragment 
of the rat insulin promoter (RIP) II (12). Transgenic mice were 
produced by microinjection  of the purified DNA fragment  into 
the male pronucleus of B6D2F~  x  B6D2F1 zygotes. Among 41 
mice born, three contained integrated copies of the transgene, as 
judged by tail genomic DNA PCR analysis, using a 5' primer cor- 
responding to the RIP II promoter (5'-TAAGGCTAAGTAGAGG- 
TGT-Y) and a 3' primer corresponding to the TNF coding region 
(5'-GAGAAGAGGCTGAGACATAG-Y), and 30 cycles of amp- 
lification (30 s at 94 ~ 30 s at 54~  and 2 rain at 72~  To deter- 
mine transgene copy numbers, Southern analysis of EcoRI-digested 
DNA was performed, yielding 2.8 and 2.4 kb fragments for the 
endogenous genes and the transgene, respectively, using hybrid- 
ization to a TNF probe. The founders were crossed to NMRI mice, 
and transgenic progeny being detected by PCR analysis of the tail 
DNA. To obtain SCID mice bearing the TNF transgene, SCID 
mice (Iffa Credo, L'Arbresle, France) were crossed with TNF trans- 
genic mice. The progeny was analyzed by PCR for presence of 
the transgene  and by lymphopenia  on blood smears for  SCID 
homozygosity after backcrossing to SCID mice. NOD mice, 5-6- 
mo-old,  were  obtained  from  the  colony  of Hans  Acha-Orbea 
(Ludwig Institute,  Lausanne Branch, Switzerland).  TNF activity 
in the blood was explored by a bioassay (13) using WEHI 164 cells 
as targets. 
When indicated,  transgenic or control  mice received the fol- 
lowing  treatments:  cyclophosphamide  (Bristol-Myers  Squibb, 
Princeton, NJ), two 300-mg/Kg i.p. injections 2 wk apart; rat mAb 
anti-mouse CD3 (14), five daily 20-/~g i.v. injections, accompanied 
when mentioned by intraperitoneal injections of human rlL-2 (Glaxo 
IMB, Geneva, Switzerland); intraperitoneal perfusions in osmotic 
minipumps  (Alzet 2002; Alza, Corp.,  Palo Alto, CA) of mouse 
rlL-1B (gift ofJ. Y. Bonnefoy, Glaxo IMB), rlFN-3, (gifts of Drs. 
N. Sarvetnick, La Jolla, CA, and G. Adolf, Behringwerke, Vienna, 
Austria) or PBS (as a control); bromo-deoxyuridine  (BrdU; Sigma 
Chemical Co.,  St. Louis, MO), either by three daily 15-rag i.p. 
injections for 3 d, or by intraperitoneal  perfusion with osmotic 
pumps  for  4 d,  total  amount,  2 mg;  streptozotocin  (Upjohn, 
Kalamazoo, MI), either 40- or 100-mg/kg i.p. daily by injection 
for 5 d; 3sSO4 (Amersham International,  Burlinghamshire,  UK) 
given as a single 5-10-mC i.p. injection, followed  by killing after 4 h. 
Histocheraistr2/, Immunoc'2/tochemistry,  and Electron MicroscoI~/.  Tis- 
sues were frozen in liquid nitrogen  or fixed either in Bouin's or 
4% glutaraldehyde and embedded in paraffin or epon 812, respec- 
tively. The following antibodies were used: rat mAb anti-mouse 
CD4 (GK1.5 [15]), CD8 (H35-17.2 [16]);/z Ig chains (gift of H. 
Bazin, Brussels), F4/80 (17), Ia (TIB 120; American Type Culture 
Collection,  Rockville,  MD), invariant chain  (gift  of N.  Koch, 
Heidelberg, Germany), ICAM-1 (18), type II cytokeratin Endo A 
(TROMA 1; gift of R. Kemler, Freiburg, Germany), anti-BrdU 
(Becton Dickinson & Co., SanJos6, CA); and guinea pig or rabbit 
IgG against porcine insulin, porcine glucagon, bovine pancreatic 
polypeptide, and synthetic stomatostatin  (gifts respectively of P. 
Wright,  Indianapolis, IN; R. H. Unger, Dallas, TX; R. E. Chance, 
Indianapolis,  IN,  and  R.  Guillemin,  La JoUa, CA).  FITC-  or 
TRITC-conjugated goat,  sheep, and rabbit  IgG antibodies were 
obtained from Biosys (Compi~gne, France) and Nordic (Tilburg, 
The Netherlands).  Autoradiographs  were performed with Ilford 
L4 emulsion. Aldehyde-fuchsin staining was done as described (18a). 
The volume density of total endocrine tissue and of B cells, was 
studied separately by the point-counting  method of morphometric 
analysis (19) on paraffin sections, stained either with hemaluneosin 
or aldehyde-fuchsin, respectively,  of the pancreata from three trans- 
genic and three nontransgenic mice. A minimum of 10,000 points 
were counted per pancreas. Statistical significance was determined 
using  the unpaired  Student-Fisher  t test  (20). Islet fibrosis was 
studied on paraffin sections stained with Gomori's silver impreg- 
nation method.  Ultrastructural  studies were performed  with an 
electron microscope (model EM 300; Philips). For explorations of 
the pancreatic islets' vascular tree, mice under general anesthesia 
(0.5-ml i.p. injection of 2.5 % tribromoethanol  in saline) were per- 
fused through the abdominal aorta with heparin and 1% glutaralde- 
hyde as fixative. The pancreata were postfixed with OsO4 before 
embedding  in epon 812. 
Results 
Development of Insulitis in  TNF  Transgenic Mice, and 
Comparison to the Insulitis Observed in Autoimmune 
NOD Mice 
Three  transgenic  founder  mice  were  obtained,  bearing 
respectively, as judged by Southern blot analysis,  1, 2, and 
8-10 copies of the insulin promoter-TNF transgene (data not 
shown). The transgenic progeny of these mice showed a very 
comparable evolution of lesions at various ages, although the 
line with the highest  copy number tended to have a more 
severe insulitis at earlier ages.  All the experiments reported 
in this work used the two lines with low copy number of 
the transgene.  Their nontransgenic littermates were used as 
controls.  As determined  by histologic examination  of var- 
ious tissues,  the lesions observed in the transgenic mice were 
restricted to the pancreatic islets. Blood samples taken at var- 
ious ages did not show detectable TNF levels, as judged by 
a bioassay. TNF mRNA was detectable in the pancreas of 
transgenic but not control mice. At 3 wk of age, lympho- 
cytes began to accumulate in the islets,  usually in a central 
localization. This was followed by a progressively increasing 
lymphoid infiltration  involving all islets (Fig.  1, A-C).  In 
mice killed between 2 and  16 too-old,  the islets were, be- 
cause of the extent  of the infiltration,  of progressively in- 
creasing size. The largest diameter, considering as islets  the 
endocrine cells and the associated lymphocytic infiltration, 
1720  Insulitis  without Diabetes in IP-TNF Transgenics Figure  1.  5 gm-thick  paraf~n  sections of pancreas of transgenic or control mice (4-6-mo-old), showing  islets of Langerhans. (.4) Three infiltrated 
islets from  a TNF transgenic  mouse  (x 62). (B). Two infiltrated  islets of a transgenic  mouse  showing  large  ductules  (x 58). (C and D) Two serial sections 
of an infiltrated  islet shown  in A; the dispersion  of B cells stained  by aldehyde-fuchsin  can be appreciated  in D (x 155); (E and F) Immunofluorescent 
staining with an antiinsulin  antibody  of islets of control (E) and transgenic (F) mice. (x250). 
of 31 islets  of seven TNF transgenic mice ranging from 5 
to  12-mo-old was 347  +_  22  #m,  and that of 25  islets  of 
five  control  mice  of comparable  ages,  181  _+  10  gm  (P 
<0.001).  The largest islets  observed had between 700  and 
800 gm in diameter. Immediately adjacent to some of these 
large islets  were extraislet accumulations of lymphoid cells 
that appeared  to correspond to dilated lymphatic channels, 
probably indicative of an enormously increased lymphocytic 
traffic. At all times during the evolution of these lesions, the 
fasting glycemias of transgenic mice were not significantly 
different from those of control littermates (average of 141 
+-  5 mg/dl, n  --  20). Using a variety of techniques, the fol- 
lowing detailed observations were made. 
The Lymphoid infiltrate Consisted  Mostly of T and B Lympho- 
cytes, and also Included  Macrophages.  Immunohistochemistry 
showed  that  most  infiltrating  cells  were  either  Thyl + 
(CD4 + or CD8 §  T, or sIg + B lymphocytes with occasion- 
ally, a few nests of plasma cells. Staining with the mAb F4/80, 
which recognizes macrophages,  showed F4/80 + cells in a 
strikingly peripheral distribution. Few of the lymphocytes 
appeared to be activated, as  judged by: (a) the scarcity of cells 
stained with anti-IL-2R antibody; and (b) the relative scar- 
1721  Higuchi  et al. Figure 2.  Ultrathin sections of intraislet capillaries (fixation by in vivo perfusion). (A) Control mouse. Capillary  with a thin rim of endothelial 
cytoplasm,  taking  by place  a fenestrated  appearance.  (B) TNF transgenic  mouse.  The endothelium  ceU lining  is typically  much higher. (C) NOD mouse. 
The aspect of the endothelium  is similar to that shown in B.  x 16,900. 
city of dividing lymphoid cells detected by BrdU labeling 
(three daily injections of BrdU on 3 consecutive d, or 4 d 
of continuous perfusion through an osmotic pump) (data not 
shown). 
Disorganization of  the Islet Architecture.  Staining by aldehyde- 
fuchsin (Fig.  1 D) or by antiinsulin antibody (Fig.  1, E and 
F) showed that ~  cells either formed a peripheral irregular 
rim in the islets where lymphocytic infiltration was predom- 
inantly central, or appeared as scattered microcolonies of cells 
in  the  massively infiltrated  islets.  Morphometric  analysis 
showed that the volume density of the total endocrine tissue 
and of B cells were not statistically different between normal 
and transgenic mice, studied between 3 and 14 mo of age. 
Presence of non-B cells  (glucagon,  somatostatin,  and pan- 
creatic polypeptide cells) in the inflamed islets  was verified 
by incubating consecutive paraffin or epon semithin sections 
with the corresponding antihormone serum.  It  should be 
noted that no clear immunofluorescence staining for MHC 
class  II  antigens  was detected on the endocrine cells  (not 
shown). 
Alteration  of the Islet Endothelial  Cells.  A  striking ultra- 
structural feature was the thickening of the endothelial cells' 
cytoplasm with a paucity of capillaries  presenting a fenes- 
trated endothelium. 82% of islet capillaries presented a clearly 
altered morphology, compared with the islet capillaries  of 
control mice (Fig.  2, A  and B). A property of the high en- 
dothelial cells of the lymph node postcapillary venules is that 
they rapidly incorporate 35804 in  a  sulfated glycoprotein, 
resulting in characteristic radioautographic labeling (21). After 
38804 injection and  autoradiography,  the islets  of control 
mice showed no labeling (Fig. 3 A), while a marked labeling 
following the vascular  outline was observed in the islets  of 
transgenic mice (Fig. 3, B and C). The presence of adhesion 
molecules on these endothelial cells was explored using an 
anti-mouse ICAM mAb on frozen sections.  Since lympho- 
cytes were stained,  a diffuse staining was observed,  and it 
was not possible to detect a distinct staining of the capillaries 
(which were not opened, as is the case with fixation under 
perfusion). 
Presence of  an Intraislet  Fibwtic Reaction.  After 2 mo of age, 
spindle-shaped cells with elongated nuclei were detectable in 
islets of transgenic mice. They were more clearly seen in mice 
in which the lymphocytic infiltration was decreased as the 
result of anti-CD3 antibody injection (see below). By elec- 
tron microscopy, they appeared to be fibroblasts,  frequently 
surrounded by bundles of collagen fibrils. The extent of this 
fibrosis  was most clearly revealed on histologic sections by 
silver  staining (Pig.  4, A  and B). 
Development of Epithelial Ductules in the Islets.  The pres- 
ence of intraislet ductules was commonly observed with in- 
creased islet alterations (Fig. 5). These ductules were stained 
by antikeratin antibodies (Fig. 5 D), and often contained lym- 
phocytes in their lumens (Fig.  5 B).  In serial  sections, the 
ductules were seen to be connected with extraislet exocrine 
ducts (Fig. 5 A), showing that they did originate from these 
ducts. A striking observation was the presence in their walls 
of isolated or sometimes contiguous/3 cells,  identified by 
histochemistry, antiinsulin antibodies,  or dectron microscopy 
(Fig.  5, B and C). On ultrathin serial sections,  these/~ cells 
were always separated from the ductular lumen by a layer, 
sometimes very thin, of epithelial cell cytoplasm (Fig. 6). No 
direct evidence for an origin of these ~ cells from precursors 
present among the ductular epithelial cells, under the form 
of cells with transitional appearance, was found. However, 
in some serial sections,  a topographical continuity was ob- 
served between fl cells located in the wall of a ductule and 
cell aggregates apparently independent of the ductules. This 
suggested that these ductules might represent a regenerating 
process for the appearance of new endocrine cells. After BrdU 
injections or perfusions as described above, about one third 
of the ductular epithelial cells were labeled. However, labeling 
of ductular B cells was only very rarely observed, and was 
not detected in other B cells. 
All these features were studied in parallel  in the pancreas 
of 5-6-mo-old NOD mice, displaying a marked insulitis most 
often without overt diabetes.  Comparable observations were 
made, with minor differences: lymphocytic infiltration tended 
to start more often at the periphery rather than in the center 
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all antibodies mentioned above, were closely comparable. De- 
velopment of intraislet ductules, however, was not observed, 
although  ductules have been seen by others in the insulitis 
of NOD  mice  (see Fig.  1 of Signore et  al.  [22]). 
Figure  3.  (A and B) Radioautographs, after 3sso4 injection, of islets 
of a control mouse (A) (grains are present only on exocrine  pancreas) and 
of a transgenic mouse (B), showing grains on the vascular walls within 
the islets. The vessels  appear dilated and empty because  of the perfusion. 
To better visualize the localization of the silver grains, the sections are 
unstained, the exposure time limited to 2 wk only. (C) Same section as 
B, stained  to show  the lymphocytic  infiltration. (A) x 360; (B and C) x 180. 
of islets,  and the level of fibrosis, as judged by silver staining 
(Fig.  4  C),  was less  marked.  The  infiltrated  islets did not 
reach the size (P <0.001) of those seen in the transgenic mice 
(average  of largest diameter of 17 islets from four mice: 217 
_+  12 #m).  Presence of F4/80 + macrophages  as a periph- 
eral rim, thickening of endothelial cell cytoplasm (Fig.  2C), 
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Development of Lesions in Islets of TNF Transgenic SCID Mice 
To explore which of the features observed in the islets of 
TNF  transgenic  mice  were secondary to  the  lymphocytic 
infiltration,  TNF  transgenic  mice were crossed with  mice 
homozygous for the SCID mutation,  which have neither T 
nor B lymphocytes (23). Transgenic SCID mice •3-mo-old 
did not show detectable lymphocytic infiltration, but a marked 
disorganization  of the normal islet architecture was nevertheless 
obvious (Fig.  4, D  and E).  Infiltration by F4/80 + cells was 
present in a peripheral pattern (Fig.  4 F), and appeared more 
marked than in non-SCID transgenic mice. Electron micros- 
copy and silver  staining for collagen fibrils  showed that  the 
altered/~ cell distribution was due to a fibrotic reaction (Fig. 
4 D) as severe as that observed in TNF transgenic non-SCID 
mice, the only consistent  difference with non-SCID mice being 
that  the B ceils  were usually arranged  in clusters of a few 
calls (Fig. 4 E). This probably simply reflects the lack of lym- 
phocytic infiltration further separating the ~ cells.  Intraislet 
ductules were rarely observed. On the other hand, ducts im- 
mediately adjacent to islets were common, but they did not 
contain ~  cells. All the cells within  the islets were strongly 
stained with anti-ICAM antibody, except/~ calls, which were 
not stained (that islet cells can be induced in vitro to express 
ICAM is known [24]).  It was thus not possible to specifically 
explore  the  endothelial  cells.  By electron  microscopy,  en- 
dothelial  changes  were  similar  to  those  described  above; 
3sSO4 incorporation was not studied. During the period of 
observation, the glycemia of these mice did not differ from 
those of non-SCID  transgenic  or control  mice. 
Attempts at Inducing Diabetes in  TNF  Transgenic Mice 
These experiments, which are summarized in Table 1, were 
performed with transgenic mice that were at least 3-mo-old, 
and  that  displayed a severe insulitis. 
Injections of  Cyclophosphamide.  In NOD mice that are not 
yet diabetic or that do not develop diabetes, one or two in- 
jections of cyclophosphamide are known to induce diabetes 
in a high percentage of cases (25). Four transgenic  mice treated 
in this way had not developed a significant  increase in glycemia 
3  mo later. 
Injections of  Anti-CD3 Antibody.  In vivo injections of anti- 
CD3 are known to stimulate T  lymphocytes and to induce 
cytokine  release  (14).  12  transgenic  mice  received  various 
schedules of anti-CD3 mAb injections, for the most part 20 
#g daily for four consecutive days. Some of these mice had 
transient and mild hypoglycemia, rather than hyperglycemia. 
After killing on day 5, the lymphocyte infiltration was usu- 
ally somewhat decreased,  making the fibroblasts easier to ob- 
serve. In two mice, this treatment was followed by injections 
of rlL-2 (5 #g, twice daily for 5 d). Lymphocytic infiltration Figure 4.  Histologic  and immu- 
nofluorescent staining of paraffin 
(A-E)  or cryostat (F) sections of 
pancreatic islets from  normal or 
TNF  transgenic mice. (A)  Silver 
stain,  control  mouse. Staining 
limited to perivascular spaces. (B) 
Silver  stain, TNF transgenic  mouse. 
Heavy deposition of stained fibrils. 
(C)  Silver stain, NOD  mouse. 
Stained fibrils are found only in the 
part of the islet infiltrated by lym- 
phoid cells. (D) Silver stain, TNF 
transgenic  SCID mouse. Heavy 
depositions of stained fibrils. (E) 
Anriinsulin  immunofluorescent 
staining of an islet from a TNF 
transgenic SCID mouse. In spite of 
the lack of  lymphocyte  infiltration, 
B cells  appear as clusters. (F) Immu- 
nofluorescent staining with F4-80 
mAb of an islet from a TNF trans- 
genic SCID mouse. Positive mac- 
rophages  are  abundant, and  are 
localized  at the periphery  of  the islet. 
(A, C, and D)  x 188. (B, E, and r  0 
￿ 
was  very marked after killing  on day  11,  without  obvious 
signs of/3 cell damage.  Glycemia did not vary significantly. 
Perfusions  of Cytokines.  In vitro, TNF, in association with 
IL-1 or IFN-7, has been observed to induce islet cell damage 
and/or increased expression of MHC class II antigens by/3 
cells (4-8, 26). Three transgenic mice received 6 #g of rlL-1/3 
in 3 d through osmotic pumps. They were killed since they 
appeared to be very sick or dying. Glycemia was low (50-60 
mg/dl).  Extensive areas  of tissue  necrosis were seen in  the 
liver  and  the  exocrine pancreas.  The  spleen  red  pulp  was 
markedly hematopoietic. The islets of these mice were similar 
to those of untreated TNF transgenic mice, and antiinsulin 
immunofluorescence showed weU-labeled/3 cells. Seven trans- 
genic mice and one control mouse received 200/zg of mouse 
rlFN-qt  as a constant  perfusion over 2 wk,  and  two  trans- 
genic mice received the solvent only. The IFN-',/-treated trans- 
genic mice (but not the normal mouse,  nor the transgenic 
mice receiving the solvent only) had changes in their liver 
(hematopoietic dusters, small loci of necrosis with occasional 
neutrophils) and exocrine pancreas (focal areas of fibrosis and 
necrosis with occasional neutrophils). Since these lesions were 
not  seen in  the  single normal  mouse treated with  IFN-3,, 
it appears probable that some TNF diffuses out of the islets 
in transgenic mice, and creates damage in synergy with IFN-% 
in particular in the exocrine pancreas.  The important point, 
however, was that the islets of these mice were not different 
from those of control TNF transgenic mice in  their struc- 
ture  and/3  cell content.  Glycemias were comparable  with 
those  of control mice. 
Injections  of  Streptozotocin.  Five consecutive daily injections 
of subdiabetogenic  doses  of streptozotocin induce diabetes 
within  a few days, often with insulitis.  This has led to the 
suggestion  that  this  is  an  autoimmune  reaction  to/3  cell 
damage (27), although  this diabetes does not seem to be T 
cell mediated (28). To explore whether small doses of strep- 
tozotocin may induce diabetes, possibly by autoimmune mech- 
anisms, more efficiently when an insulitis is already present, 
several groups of 3-10 TNF transgenic mice and their con- 
1724  Insulitis  without  Diabetes in IP-TNF Transgenics trois were subjected to serial injections of streptozotocin (40 
or  100 mg/kg  per injection).  No diabetes was induced by 
low doses of this  drug,  whereas with  high  doses, 6  of 13 
(46%) transgenic  and 10 of 13 (77%) control mice became 
diabetic. Thus, mice with insulitis are not more susceptible 
to developing diabetes after this treatment  than are control 
mice. 
Presence of an Antigenic  Viral Antigen  on ~  Cells.  TNF 
transgenic mice were crossed with mice bearing a transgene 
that causes the expression of the lymphoehoriomeningitis virus 
glycoprotein (LCMV gp) on their islet B cell membranes (10). 
These mice do not respond  spontaneously to this antigen, 
but they are not tolerant  since,  when infected with the live 
LCMV virus, they develop insulitis and diabetes within a few 
days (10). Mice carrying the two TNF and LCMV gp trans- 
genes did not become spontaneously diabetic over a period 
of 6 mo of observation.  They were not tolerant  to the an- 
tigen,  since when injected with the live virus,  they became 
diabetic within a few days, much as their control littermates 
bearing only the LCMV gp transgene.  Four mice carrying 
the two transgenes also received perfusions of IFN-3' (15 d), 
using the same protocols as described above for the TNF trans- 
genie mice,  with  comparable results. 
Figure  5.  Intraislet ducts in transgenic mice. (A) Aldehyde-fuchsin 
staining of the pancreas from a TNF transgenic mouse. A branch from 
an interlobular duct is entering an infiltrated islet. (B) Aldehyde-fuchsin 
staining. Positive  ~ cells embedded  among the epithelial cells of ductule 
are especially  striking. Around the ductule, a lymphocyte  infiltrate replaced 
most/3 cells, and numerous lymphocytes  are also present in the ductule's 
Discussion 
The permanent  production of TNF-ol by pancreatic islet 
cells results in a damage restricted to the islets of Langer- 
hans, the major features of which are: lymphocytic insulitis, 
endothelial cell alterations, fibrotic reaction, disorganization 
of the arrangement  of the endocrine cells,  and development 
of epithelial ductules containing,  by places,  B cells in their 
walls. The lack of lesions in the exocrine regions of the pan- 
creas  and the good health conditions  observed in the three 
lines  of transgenic mice studied suggests that  the release  of 
TNF-ol remained low. This may be due to the presence of 
the entire 3' untranslated  region  of TNF in the transgene. 
This region indeed exerts a negative effect, not only on TNF 
mKNA  stability, but  also on its  translation  (29). 
The lesions observed in TNF transgenic mice can be ana- 
lyzed from two perspectives: the chronic inflammatory reac- 
tion elicited by continuous local TNF release, and the patho- 
genesis  of autoimmune  diabetes,  the  first  stage  of which 
presents,  in  NOD  mice,  comparable lesions. 
The insulitis  consisted of a progressively  growing lymphoid 
infiltration  made  of CD4 +  and  CD8 +  T  lymphocytes,  B 
lymphocytes and, to a lesser extent, macrophages. At no time 
was a polymorphonuclear infiltration, even limited, observed. 
With age, the lymphoid cell infiltration became so large that 
the average  islet diameter was doubled.  This appears to be 
associated with an intense local cell traffic,  as suggested by 
the dilated lymphatic  channels  full of packed lymphocytes 
lumen. (C) Immunofluorescence  with antiinsulin shows staining of the 
numerous fl cells  in the wall of an intraislet ductule. (/9) lmmunofluores- 
cence with anticytokeratin antibody to stain ductule epithelial cells (see 
Fig. 6). (A)  x240. (B)  x250. (C)  x280. (D)  x312. 
1725  Higuchi  et al. Figtu~  6.  Electron  microscopic  appearance  of  intraislet duc- 
tules of  TNF transgenic mice  containing/5 cells  in their wall. 
cells are not in contact with the ductule lumen, but are 
covered by a thin sheet of epithelial cell cytoplasm. This ex- 
plains the staining with anticytokeratin antibody shown in 
Fig. 5 D.  x13,500. 
often seen adjacent to the infiltrated islets.  The main cause 
of this increased local traffic is likely to be endothelial changes 
resulting  from  TNF  action. 
Two striking  alterations  of the islet capillary walls were 
indeed seen: a general cytoplasmic endothelial thickening with 
loss of the fenestrated structure of the normal islet capillaries, 
and the ability to incorporate 3sSO4 in capillary walls after 
in vivo injection. Sulfate incorporation is a characteristic fea- 
ture of the peculiar high endothelial cells of the lymph nodes' 
postcapillary venules (21), also called high endothelial venules, 
which  are a site of massive emigration  of circulating  lym- 
phocytes from  the blood.  In  these cells,  this  sulfate group 
is present on the carbohydrate moiety of a mucin-like glyco- 
protein  (30) which functions  as a "vascular adressin"  (31). 
It is a ligand to a t-selectin (32) of lymphocytes, an adhesion 
protein  with  a lectin  domain  which  functions  as  a lymph 
node "homing receptor" (33-35). Expression of this selectin 
ligand is induced by TNF on endothelial cells in culture (36), 
as is that  of other adhesion proteins,  namely ICAM-1 (37, 
38),  endothelial  leukocyte  adhesion  molecule  (ELAM-1) 
(39-41), and vascular cell adhesion molecule (VCAM-1) (42). 
Presence of these molecules on the transgenic islet endothelial 
cells could not be explored,  either because many other islet 
cells were stained,  as was the case for ICAM-1,  or because 
Table  1.  Attempts  at Eliciting Diabetes in  TNF  Transgenic Mice 
Glycemia* >250 mg/dl  and/or 
Protocol used  histologic  f3 cell damage in  recipients  Known effects* 
1.  Cyclophosphamide  No 
(repeated injections) 
2.  Anti-CD3  antibody  No 
_+IL-2 (5 d) 
3.  IL-1/~ perfusion  (3 d)  No 
4.  IFN-y perfusion  (15 d)  No 
5.  Streptozotocin: 
40 mg/kg/d,  5 d 
100 mg/kg/d,  5 d 
6.  ~  cells bearing  a viral Ag 
7.  As 6,  plus viral infection 
8.  As 6,  plus  IFN-3, perfusion  (15 d) 
No 




Triggers  diabetes in NOD mice with 
insulitis  and no diabetes 
Triggers  cytokine release by T  cells; 
activates T  cells 
Damages  islet cells in  vitro 
In vitro,  increases MHC class II antigen 
expression  on B cells and  synergizes TNF 
action,  including  islet cell damage 
Subdiabetogenic  damage  to ~  cells; 
reported  to trigger  cell-mediated 
autoimmune  response to ~  cells 
No immune  response in mice without 
viral infection 
Viral infection  triggers  diabetes 
Combines  nos.  6 and 4 
* Nonfasting values 
* See text for details and references. 
1726  Insulitis  without Diabetes in IP-TNF Transgenics of the lack of relevant antibodies.  The endothelial changes 
observed in the islets of TNF transgenic mice are likely to 
be instrumental in the development of the insulitis, inducing 
a lymphocytic traf~c resting on mechanisms comparable with 
those operative at the level of lymph nodes' high endothelial 
venules. 
Together with lymphoid infiltration, the other major al- 
teration leading to disorganization of endocrine cells within 
the islets of the TNF transgenic mice was fibrosis. This was 
not secondary to the lymphocytic infiltration, since fibrosis 
was also prominent in TNF transgenic SCID mice, which 
have no lymphocytic infiltration. Fibrosis may be related to 
macrophage infiltration, which was particularly conspicuous 
in TNF transgenic SCID mice. Previously,  TNF has been 
found to be involved in fibrotic reactions (43), and in partic- 
ular, as judged by the preventive effect of anti-TNF antibody 
treatment,  on  some  fibrosing  pneumopathies  (44,  45). 
Whether TNF acts indirectly, by enhancing the release and 
processing of fibrogenic cytokines, such as TGF-fl, has not 
been  determined.  The  extent  of the  fibrotic  reaction  at 
the site of prolonged TNF release may vary depending upon 
the nature of the cellular infiltrate and the composition of 
the surrounding tissue. Islet fibrosis has also been observed 
in human insulin-dependent diabetes  (46). 
The last prominent alteration in the pancreatic islets was 
the appearance of epithelial ductules containing, by places, 
3  cells in their walls, sometimes arranged in a more or less 
continuous row. Serial sections showed the connection of these 
ductules with extraislet ducts. Is this a process of regenera- 
tion, starting from exocrine ducts and leading to the neofor- 
mation of endocrine cells? Although strongly suggested by 
the topographical organization of these fl cell-containing duc- 
tules, this hypothesis could not be ascertained,  since no cells 
displaying intermediate features compatible with progressive 
differentiation into ~/cells of precursors  located in the duc- 
tular walls were detected. What could be the inducing mech- 
anism(s) of ductular development? A primary role of B cell 
damage or disorganization does not seem likely, since these 
structures have not been described after direct fl cell damage 
occurring after streptozotocin treatment (47). Local release 
of cytokines is an attractive possibility. Although TNF-c~ it- 
self is not known to act directly upon epithelial cell growth, 
it does trigger cytokine release from a variety of cell types. 
Macrophages, for instance, which are present in the insulitis, 
may release, among many other cytokines, TGF-o~, an epi- 
thelial cell growth factor (48). Can a putative process of fl 
cell regeneration play a significant role in the lack of progres- 
sion towards diabetes of the TNF-mediated insulitis? After 
injections or perfusion of BrdU, the extent of labeling of the 
ductular epithelial cells did not indicate very rapid prolifera- 
tion, and only very few fl cells were found to be labeled. 
However, it seems plausible that a slow but constant process 
offl cell regeneration might play some protective role against 
the occurrence of diabetes in conditions where fl cell injury 
does not occur at a very rapid rate. Very extensive prolifera- 
tion of intraislet ductules is observed in the form of diabetes 
developed by db/db mice, although the pathogenic mecha- 
nisms of this disease are still obscure (49, 50). It is interesting 
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to note that in human insulin-dependent  diabetes, comparable 
intraislet, lymphocyte-containing  ductules have also been ob- 
served (46). 
When the TNF-mediated insulitis was compared with the 
autoimmune insulitis of NOD mice, two salient observations 
emerged. First, the TNF-mediated lesions bear, in almost aU 
details discussed above except the development of ductules, 
a marked resemblance to those found in NOD mice analyzed 
in parallel in the present study. Second, in spite of the in- 
creasing extent with age of the insulitis of TNF transgenic 
mice, overt diabetes never developed, at least during the long 
period of observation (up to 16 too). Similarly, in the first 
phase of the autoimmune disease in NOD mice, there is a 
marked insulitis without obvious decrease in 3  cells and 
without clinical diabetes. CD4 + T cell clones have been ob- 
tained from the lymphocytes infiltrating the islets of NOD 
mice at this stage of the disease. These clones proliferate  in 
vitro in the presence of islet cells of NOD mice only, and, 
after in vivo injection to young NOD mice, lead to the rapid 
development of insulitis without diabetes (51). TNF may be 
a mediator of the NOD insulitis.  TNF mRNA has indeed 
been detected by in situ hybridization in the NOD insulitis 
(3). This would not exclude a contribution of TNF-3, which 
shares the same receptors, and of II.,1, which has comparable 
effects on endothelial cells (52).  The puzzling observation 
that several weekly injections of TNF for several months in 
NOD mice retard insulitis and subsequent diabetes (53, 54) 
may seem to argue against this hypothesis. However,  there 
are examples of desensitization to TNF effects by systemic 
injections of TNF which could explain this apparent paradox 
(55). In any event, the point that must be stressed most force- 
fully in the present context is that, in a large proportion of 
NOD mice (i.e., 20-30% of females and 80-90% of males), 
which all have initial insulitis of comparable severity, a second, 
diabetic phase  of the  disease  never  develops.  To  develop 
the fl cell injury resulting in diabetes, which occurs around the 
sixth  month,  secondary events  are  necessary,  leading  to 
the appearance of new islet T  cell subpopulations, perhaps 
as the result of recognition of new antigens. CD4 + T  cell 
clones have indeed been obtained from NOD mice in the 
diabetic phase which destroy NOD islet cells in vitro (56), 
and induce the rapid appearance of diabetes  after injection 
into  mice presenting  insulitis  only  (57).  Activated  islet 
CD8 + T cells are also capable of cytotoxicity against islet 
cells in vitro (58). In any event, the respective roles of CD4 + 
and CD8 + T lymphocytes in the development of initial in- 
sulitis and of subsequent diabetes are still a matter of con- 
troversy  (59,  60).  Some BB rats,  although diabetes-prone, 
fail to develop diabetes. In these rats too, an insulitis has been 
observed (61). 
Thus, in spite of the severity of their insulitis,  the TNF 
transgenic mice may lack secondary events required to precipi- 
tate the fl cell damage. Alternatively, or in addition, the lym- 
phocytes present within the transgene-induced insulitis may 
lack antigenic stimulation, since the transgenic mice do not 
have the unique genetic background alterations, in particular 
within the MHC, which is the basis of the susceptibility of 
NOD mice to diabetes. A variety of protocols, listed in Table 1, was used, to try to mimic secondary events capable of in- 
ducing diabetes, or to induce an antigenic stimulation within 
the islets,  or a combination of both.  This included cyclo- 
phosphamide treatment (known to rapidly induce the appear- 
ance of diabetes and to considerably increase its incidence in 
NOD mice [25]), T lymphocyte stimulation, and constant 
perfusion of cytokines reported to strongly synergize with 
TNF in vitro to induce islet cell damage (4-8) and/or to in- 
crease/3 cell expression of MHC class II antigens and thus 
the presentation of antigenic peptides (26, 62). None of these 
protocols induced overt diabetes or immunohistocbemical signs 
of/3 cell damage. The lack of effect of cyclophosphamide in- 
dicated that the transgenic insulitis differs from the NOD 
insulitis, perhaps because of the lack of a proper antigenic 
stimulation in the absence of a NOD genetic background. 
It is intriguing that the constant presence of high doses of 
circulating IFN-~/for 2 wk did not have, in mice releasing 
TNF in their islets  and already having a severe insulitis,  a 
diabetogenic effect, since mice bearing an IFN-qr transgene 
under the control of the insulin promoter develop diabetes 
with some degree of islet lymphocytic infiltration (9). Evi- 
dence has been presented for the existence in these mice of 
circulating lymphocytes specifically cytotoxic to syngeneic 
normal islet cells, i.e.,  of a tissue-specific  cell-mediated au- 
toimmunity (63). In NOD mice, anti-IFN-3~ antibody treat- 
ment decreases  the incidence of diabetes triggered by cy- 
dophosphamide injection (64). The possibility that an intraislet 
simultaneous release  of these two  cytokines (by breeding 
double transgenic mice) indeed has a synergistic effect on di- 
abetes  occurrence could unfortunately not be explored. 
Two lines of evidence argue against the interpretation that 
the lack of progression of the TNF-mediated insulitis towards 
diabetes might simply reflect the lack of antigenic determinants 
borne by B cells. First, repeated injections of various amounts 
of subdiabetogenic doses of streptozotocin, which repeatedly 
damages B cells (27),  did not result in an incidence of dia- 
betes in TNF transgenic mice higher than that observed in 
control littermates. Second, and more decisively, mice with 
a strong insulitis and expressing a viral antigen on islet 
cell membranes were obtained by crossing TNF transgenic 
mice with mice bearing a LCMV-gp transgene under the con- 
trol of an insulin promoter (10, 65).  These last  transgenic 
mice do not spontaneously respond to the LCMV-gp antigen 
(10). They have normal glycemias and intact islets, but when 
exposed to a strong antigenic stimulus (infection with the 
live virus), they develop an acute diabetes after 9-11 d, with 
an insulitis in which specific cytotoxic CD8 + cells can be 
found (10). Mice bearing the two LCMV-gp and TNF trans- 
genes did not develop diabetes spontaneously, at least not 
over a 6-mo period of observation. Perfusion with IFN-y 
during 2 wk did not lead to a rapid increase in glycemia, 
which, however, was observed in these mice 1 wk after in- 
fection with live virus (indicating that they had not been ren- 
dered tolerant). Taken together, these results indicate that an- 
tigen presentation on/3 cells is by itself not able to efficiently 
stimulate specific lymphocytes among the large amounts of 
lymphocytes that circulate through islets  as a result of the 
insulitis, even in conditions considered to enhance antigen 
presentation such as exposure to IFN-3'. Recently, mice bearing 
an IL-2 transgene under the control of the rat insulin pro- 
moter were described. Some of these mice developed an in- 
sulitis,  without evidence of autoimmunity to islet antigens, 
in particular diabetes,  nor of recognition of a foreign MHC 
class I antigen (expressed on/3 cells by the use of double trans- 
genic mice) (66). 
The conclusion of these last observations is that, to obtain 
/3 cell destruction leading to diabetes,  severe insulitis, release 
of cytokines, and presence of antigenic determinants on/3 
cells are not sufficient. Antigen-bearing B cells may be ade- 
quate targets only for T  lymphocytes already stimulated by 
other cells presenting these antigenic determinants. The in- 
creased lymphocytic traffic in the islets resulting from insu- 
litis may increase the changes of contact between specifically 
stimulated T lymphocytes and antigen-bearing/~ cells, and 
thus enhance the risk of diabetes or accelerate its emergence. 
The concept that lymphocytic insulitis may be by itself only 
potentially diabetogenic, i.e., may represent but an increased 
risk factor for specific and extensive/~ cell damage, provides 
an explanation for the existing discrepancy between the oc- 
currence of insulitis and that of diabetes in autoimmune NOD 
mice. In human autoimmune diabetes too, there is evidence 
for a long period of antiislet autoimmunity before the abrupt 
clinical  occurrence of diabetes (67). 
In summary, the study of TNF transgenic mice has shown 
that: (a) a slow local release of TNF leads to a massive lym- 
phoid cell infiltrate, probably resulting mainly from endothelial 
cell alterations, accompanied by local fibrosis  and ductular 
proliferation, which may represent a process of endocrine 
regenerations;  and  (b)  a  lymphoid insulitis,  whatever its 
severity,  is not by itself sufficient to create diabetes.  It ap- 
pears that lymphocyte stimulation by APCs other than ~ cells 
is necessary for diabetes to develop. 
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